New diabetes drug BGM0504 takes on semaglutide in major trial

NCT ID NCT07064486

Recruiting now Disease control Sponsor: BrightGene Bio-Medical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial compares a new injectable drug, BGM0504, to the established drug semaglutide (Ozempic) in 477 adults with type 2 diabetes. All participants also take metformin. The study measures how well each drug controls blood sugar and weight over 24 weeks. The goal is to see if BGM0504 is a safe and effective alternative.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BGM0504 (a new injectable drug for diabetes)
What this could lead to: If successful, BGM0504 could offer a new once-weekly option to help control blood sugar and weight in people with type 2 diabetes.
What could go wrong: This is an early-phase 3 trial, so results may not confirm superiority over semaglutide. Side effects and long-term safety are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES (T2DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES (T2DM)

Contacts and locations

Locations

RS Universitas Indonesia
RECRUITING

Depok, West Java, Indonesia
RSUP Fatmawati
RECRUITING

Jakarta, Indonesia
RSUP Persahabatan
RECRUITING

Jakarta, Indonesia
RSUPN Dr. Cipto Mangunkusumo
RECRUITING

Jakarta, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.